INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.02
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.96

20 Nov
2024

-0.010

OPEN

$3.00

-0.34%

HIGH

$3.00

147,834

LOW

$2.92

TARGET
$3.10 4.7% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 26.0 11.3 xxx
DPS (cps) xxx 5.8 8.6 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx - 3.3% 47.4% xxx
PE Ratio xxx N/A 25.7 xxx
Dividend Yield xxx N/A 2.9% xxx
Div Pay Ratio(%) xxx N/A 75.7% xxx

Dividend yield today if purchased 3 years ago: 1.19%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-26.0
DPS All xxxxxxxxxxxxxxx5.8
Sales/Revenue xxxxxxxxxxxxxxx469.7 M
Book Value Per Share xxxxxxxxxxxxxxx129.0
Net Operating Cash Flow xxxxxxxxxxxxxxx66.2 M
Net Profit Margin xxxxxxxxxxxxxxx-12.92 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-17.99 %
Return on Invested Capital xxxxxxxxxxxxxxx-8.89 %
Return on Assets xxxxxxxxxxxxxxx-7.67 %
Return on Equity xxxxxxxxxxxxxxx-17.99 %
Return on Total Capital xxxxxxxxxxxxxxx6.00 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx28.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx16 M
Long Term Debt xxxxxxxxxxxxxxx342 M
Total Debt xxxxxxxxxxxxxxx358 M
Goodwill - Gross xxxxxxxxxxxxxxx373 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx42 M
Price To Book Value xxxxxxxxxxxxxxx2.07

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx23.9 M
Capex % of Sales xxxxxxxxxxxxxxx5.08 %
Cost of Goods Sold xxxxxxxxxxxxxxx366 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx62 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

28/08/2024

1

Outperform

$2.90

-2.03%

Macquarie's forecasts suggest double-digit EPS accretion for Integral Diagnostics over FY25/FY26 assuming cost synergies pertaining to the Capitol Health ((CAJ)) merger are realised.

After reviewing FY24 results, the broker highlights the EBITDA margin expanded to 19.5% (as expected) with ongoing expansion anticipated in FY25 as head-count reductions annualise.

The target rises to $2.90 from $2.85. Outperform.

FORECAST
Macquarie forecasts a full year FY25 dividend of 8.00 cents and EPS of 11.00 cents.
Macquarie forecasts a full year FY26 dividend of 10.00 cents and EPS of 13.80 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

26/09/2024

3

Hold

$2.50

-15.54%

Given separate regional concentration, Canaccord Genuity doesn't anticipate any regulatory problems for the Capitol Health/Integral Diagnostics tie-in, which is set for November, pending shareholder approval.

The analysts see potential for material margin expansion via referring benefits and further structural cost-savings (i.e. incorporating the teleradiology offering across the enterprise).

The broker's Hold rating and $2.50 target are maintained for Integral Diagnostics.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 6.80 cents and EPS of 10.00 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 9.00 cents and EPS of 13.00 cents.

Wilsons

xx/xx/xxxx

1

xxxxxxx xx xxxxxxxxxx xxxx xxxxxx xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

IDX STOCK CHART

FNArena News on IDX

1
Rudi’s View: The Importance Of ‘Quality’ Growth

Nov 21 2024 - Rudi's View
2
Rudi’s View: A Rally With No Earnings Support

Nov 14 2024 - Rudi's View
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 08-11-24

Nov 08 2024 - Weekly Reports
4
Rudi’s View: Trump Returns, What Now?

Nov 07 2024 - Rudi's View
5
Australian Broker Call *Extra* Edition – Nov 06, 2024

Nov 06 2024 - Daily Market Reports

Latest Medical Equipment & Devices News

1
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
2
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
3
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
4
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
5
ResMed Silences The Doubters

Apr 29 2024 - Australia
6
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
7
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
8
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
9
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
10
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps